Amneal Pharmaceuticals, Inc. AMRX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $127.93M+273% | -$73.88M-51.6% | -$48.72M+80.9% | -$254.79M— | ||
| $31.95M+15.1% | $27.77M+3.5% | $26.82M-15.8% | $31.85M+12.1% | ||
| $22.43M-22.9% | $29.1M+152% | $11.55M+34.4% | $8.6M-6.6% | ||
| $120.57M— | —— | —— | $79.72M+237% | ||
| $87.03M-33.3% | $130.53M+3.4% | $126.18M+23.2% | $102.4M— | ||
| $21.32M-90.9% | $235.14M— | —— | —— | ||
| $20.17M— | —— | —— | -$9.88M— | ||
| -$4.73M-211% | -$1.52M+84.7% | -$9.92M-12.4% | -$8.83M-56.7% | ||
| —— | —— | -$61.21M-74,972% | $81.75K— | ||
| $339.99M+15.2% | $295.1M-17.3% | $356.92M— | —— | ||
| $70.06M+34.9% | $51.92M+20.1% | $43.22M-6.9% | $46.41M-2.8% | ||
| $15.51M+5.9% | $14.65M-34.6% | $22.39M-46.4% | $41.8M+2,359% | ||
| —— | —— | —— | —— | ||
| -$112.26M-78.2% | -$63M+9.0% | -$69.19M+60.3% | -$174.31M+10.2% | ||
| $2.69B— | —— | $217.73M— | $0— | ||
| $1.96M+69.8% | $1.15M+156% | $451K-31.9% | $662K-22.4% | ||
| $22.28M+180% | $7.95M+234% | $2.38M-33.4% | $3.57M+34.0% | ||
| —— | —— | —— | —— | ||
| —— | -$211.79M+0.4% | -$212.57M— | —— | ||
| -$1.68M-67.0% | -$1.01M— | —— | -$5.71M— | ||
| $194.52M+907% | $19.31M— | —— | -$221.51M— | ||
| $197.85M-24.9% | $263.52M+36.7% | $192.81M+35.1% | $142.72M+17.2% | ||
| $21.33M+30.3% | $16.37M— | —— | $12.65M+181% | ||
| $22.43M-22.9% | $29.1M+152% | $11.55M+34.4% | $8.6M-6.6% | ||
| $223.57M-5.3% | $236.19M+3.0% | $229.4M-4.5% | $240.18M+2.9% | ||
| —— | -$7.19M— | —— | -$15.19M-8,580% | ||
| —— | -$482K— | —— | -$646K+91.4% | ||
| —— | $54.44M+454% | $9.83M— | —— | ||
| $20.17M— | —— | —— | -$9.88M— | ||
| —— | —— | $3.37M— | —— | ||
| $85.96M-11.0% | $96.56M+29.3% | $74.69M+46.2% | $51.1M-6.5% | ||
| -$4.73M-211% | -$1.52M+84.7% | -$9.92M-12.4% | -$8.83M-56.7% | ||
| $15.51M+5.9% | $14.65M-34.6% | $22.39M-46.4% | $41.8M+2,359% | ||
| $28.78M+242% | $8.42M— | —— | —— | ||
| —— | —— | —— | —— | ||
| $2.09M— | $0— | $0— | —— | ||
| $74.97M+105,496% | $71K-100.0% | $162.42M+9,666% | $1.66M— | ||
| —— | —— | $0— | —— | ||
| —— | $0-100% | $217.73M— | $0— | ||
| -$2.81B-1,388% | -$188.92M+54.4% | -$414.08M-236% | -$123.27M— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $21.33M+30.3% | $16.37M— | —— | $12.65M+181% | ||
| —— | —— | —— | —— | ||
| $269.93M+11.0% | $243.18M-25.3% | $325.71M— | —— | ||
| $269.93M+11.0% | $243.18M-25.3% | $325.71M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amneal Pharmaceuticals, Inc. generate?
- Amneal Pharmaceuticals, Inc. (AMRX) generated $305.8M in operating cash flow over the trailing twelve months.
- What is Amneal Pharmaceuticals, Inc.'s free cash flow?
- After $65.1M of capital expenditures, Amneal Pharmaceuticals, Inc.'s free cash flow was $240.8M over the trailing twelve months, down 4.1% year over year.
- Where does Amneal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
